ICU Medical, Inc. — Q3 2010 Form 10-Q
Business context and reporting period. ICU Medical develops, manufactures and sells disposable medical devices for vascular therapy, oncology and critical care. This unaudited filing covers the quarter and nine months ended September 30, 2010; financial amounts below are in U.S. dollars unless noted. The company operates as one business segment. Its 2009 acquisition of Hospira’s critical care product line shifted sales toward direct and distributor channels.
Financial results and liquidity
| Metric | Q3 2010 | Q3 2009 | Nine months 2010 | Nine months 2009 |
|---|---|---|---|---|
| Total revenue | $75.7 million | $54.0 million | $209.0 million | $161.7 million |
| Gross profit / margin | $34.0 million / 45% | $25.0 million / 46% | $93.1 million / 45% | $77.4 million / 48% |
| Operating income | $14.6 million | $7.6 million | $32.8 million | $27.0 million |
| Net income | $9.0 million | $6.3 million | $20.9 million | $19.1 million |
| Diluted EPS | $0.65 | $0.42 | $1.51 | $1.27 |
- Q3 revenue increased 40% and net income increased 42% year over year. Nine-month revenue rose 29%, while net income rose about 9%.
- Nine-month operating cash flow was $18.8 million, down from $40.2 million. Management cited higher receivables and lower accounts payable among the principal working-capital uses.
- Cash, cash equivalents and investments totaled $81.9 million at September 30, versus $108.1 million at December 31, 2009. Cash and equivalents alone were $65.7 million. Current assets were $195.4 million and current liabilities $26.6 million.
- No debt is reported on the balance sheet. Nine-month capital expenditures were $17.8 million; net investing cash flow was positive $23.3 million, largely reflecting net investment-security sales. Financing cash outflow was $25.5 million, including $28.6 million of share repurchases.
- Stockholders’ equity was $262.3 million. Treasury stock increased to $45.5 million from $19.9 million at year-end 2009.
Material changes versus prior periods
- Critical care sales increased after ICU Medical took over commercial rights and assets from Hospira; the comparison is affected by the transition from Hospira sales to distributor and direct sales. Nine-month domestic distributor/direct sales increased 97%, while U.S. sales to Hospira decreased 6%.
- Q3 custom-product sales increased 46% to $28.3 million; CLAVE sales rose 26% to $25.7 million. Management attributed growth to unit gains, customer conversions, critical care channel changes and additional Hospira orders.
- Gross margin declined year over year, primarily because of critical care integration and higher freight costs, partly offset by manufacturing efficiencies. SG&A increased in dollars but declined as a share of revenue; R&D expense also increased.
- Effective tax rate was 38% in Q3 versus 21% a year earlier, and 36% for the first nine months versus 32% in 2009. Lower interest income contributed to the nine-month decline in other income.
Outlook, risks and contingencies
- Management estimated 2010 gross margin of about 45%, SG&A at about 27.5% of revenue, R&D at 1.5%–2.0% of revenue, and an effective tax rate of about 36%. These are estimates, not guarantees.
- Management forecast 2010 capital expenditures of $21–$23 million, including the Mexico expansion and Slovakia plant, and expected to fund them from existing cash. Slovakia began operations in Q3, with initial shipments expected in Q4; the Mexico expansion was expected to finish in early 2011.
- Management expected continued growth in custom, critical care and international sales, and additional Q4 CLAVE and custom infusion orders tied to Hospira’s product changes and potential market demand. Such orders may be temporary; the filing does not guarantee the anticipated volumes or growth.
- Hospira remained a major customer: 47% of Q3 revenue and 43% of nine-month revenue came from Hospira; it represented 46% of receivables at September 30. Dependence on this relationship, customer ordering patterns, competition, product execution and integration are material risks.
- Other disclosed risks include seasonal and healthcare-market fluctuations, foreign exchange and input costs, supply availability, regulatory matters, and successful launch and sale of new products. The filing reported no material change to the risk factors in the 2009 Form 10-K.
- Management said routine legal proceedings were not expected to materially affect results. ICU Medical’s patent case against RyMed was scheduled for trial on December 13, 2010. Indemnification arrangements have no stated maximum exposure, though management did not expect material liabilities. Contractual obligations listed totaled $7.2 million, including $5.4 million of capital purchase obligations.
- Disclosure controls were reported effective, with no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether Hospira-related orders and critical care channel-transition gains persist, and how customer concentration evolves.
- Whether gross margins recover or remain pressured by integration, freight and production costs.
- Whether operating cash flow improves as receivables, inventory and payables change, and whether planned capital spending stays within the $21–$23 million estimate.
- Execution and shipment timing at the Slovakia facility and completion of the Mexico expansion.
- Outcome and potential financial effect, if any, of the RyMed litigation and other contingencies.